PuSH - Publikationsserver des Helmholtz Zentrums München: CBL mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Polzer, H. ; Janke, H. ; Schmid, D. ; Hiddemann, W. ; Spiekermann, K.

CBL mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.

Exp. Hematol. 41, 271-280 (2013)

DOI

PMC

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

In addition to overexpression and the occurrence of activating mutations, receptors can be aberrantly activated by impaired downregulation. Here, it is shown that an oncogenic mutant of the ubiquitin ligase CBL (CBLΔexon8), which is found in AML patients, predominantly cooperates with receptor tyrosine kinase (RTK) class III receptors (PDGFRA, PDGFRB, KIT and FLT3), but not with non-class III RTKs or cytokine receptors, to induce IL-3-independent growth of Ba/F3 cells. In cells co-expressing RTK class III/CBLΔexon8, receptor internalization was delayed and cells were protected from apoptosis after cytokine withdrawal. Ligand-stimulated Ba/F3 cells and AML cell lines co-expressing the CBL deletion mutant and FLT3 showed enhanced AKT phosphorylation. Combined pharmacological inhibition of the PI3K/AKT pathway and FLT3 had an additive effect on cell proliferation. The transforming potential of the CBL mutant was completely abolished by the mutation of the CBL PTB domain and was decreased by the mutation of tyrosines 589 and 591 in the juxtamembrane domain of FLT3. A constitutively active AKT1 mutant (E17K) recapitulated the phenotype induced by the CBL deletion mutant in Ba/F3 cells. This study reveals FLT3-CBL interaction sites and the AKT pathway as critical mediators of transformation by oncogenic CBL mutants.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

2.905

0.820